Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study

This publication has 32 references indexed in Scilit:

• A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder
  International Clinical Psychopharmacology, 2013
• Efficacy and Safety of Desvenlafaxine 50 mg/d for Prevention of Relapse in Major Depressive Disorder
  The Journal of Clinical Psychiatry, 2013
• Treatment of Comorbid Anxiety and Depression with Escitalopram: Results of a Post-Marketing Surveillance Study
  Pharmacopsychiatry, 2012
• Antidepressant Response in Major Depressive Disorder: A Meta-Regression Comparison of Randomized Controlled Trials and Observational Studies
  PLOS ONE, 2011
• Efficacy, Safety, and Tolerability of Desvenlafaxine 50 mg/d for the Treatment of Major Depressive Disorder
  The Primary Care Companion For CNS Disorders, 2010
• Desvenlafaxine: A new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder
  Clinical Therapeutics, 2009
• Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies
  Clinical Therapeutics, 2009
• Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial
  International Clinical Psychopharmacology, 2008
• Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder
  Current Medical Research and Opinion, 2008
• The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder
  American Journal of Psychiatry, 2003